The company said that since this manufacturing facility is already
under USFDA import alert and presently not doing any US business, this
will have no impact on company's current on-going business activities.
The USFDA inspection of its Piparia (Silvassa) formulations
manufacturing unit in August resulted in three observations.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-health-regulator-finds-silvassa-unit-non-compliant-with-cgmp-ipca-labs/articleshow/72237734.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment